🏛️ Verified NIH Record • Updated 2026-07-08
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors (NCT03220646)
A Phase 2 Study of Abemaciclib in Patients With Recurrent Primary Brain Tumors
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.
Who can join: Review the eligibility criteria below.
Location: Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only) — Hartford, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only) — Hartford, Connecticut
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
- Memorial Sloan Kettering Commack (All Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Lehigh Valley Health Network — Allentown, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Brain Tumor
- Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound — Toronto, Ontario
- Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study — Memphis, Tennessee
- Understanding the Late Effects of Surviving a Pediatric Brain Tumor — New York, New York
- Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG — Toronto, Ontario
- Observational Trial of the Impact of Radiation Dose in Children With Brain and Skull Base Tumors. — Miami, Florida
Explore by condition: All Brain Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.